search
Back to results

Engaging Patients in Heart Failure Management

Primary Purpose

Congestive Heart Failure

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PHR Messaging
Sponsored by
Parkview Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Congestive Heart Failure focused on measuring Cardiac Resynchronization Therapy Devices, Cardiac Resynchronization Therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

FOCUS GROUPS

Inclusion Criteria:

  1. Remotely monitored with CRT-CIED

    • focus groups 1 & 2: implant ≤ 12 months
    • focus groups 3 & 4: implant ≥ 12 months
  2. Current patient of PPG-Cardiology
  3. History of HFrEF (heart failure in the setting of reduced ejection fraction)
  4. Access to computer and internet
  5. *Ability to provide informed consent
  6. *Age ≥ 18 years

    • 5 and 6 must apply to caregivers, partners, and/or support persons

Exclusion Criteria:

  1. Not remotely monitored with CRT-CIED
  2. Not current patient of PPG-Cardiology
  3. No history of HFrEF
  4. Pacemaker dependent
  5. Does not have access to computer and internet
  6. *Inability to provide informed consent
  7. *Age < 18 years
  8. *Does not meet inclusion criteria

    • Only 6, 7, and 8 apply to caregivers, partners, and/or support persons

TECHNOLOGY TRIAL

Inclusion Criteria:

  1. Remotely monitored with Biotronik CRT-CIED for more than 60 days
  2. Ability to provide informed consent
  3. Age ≥ 18 years
  4. Willing to have MyChart or proxy to MyChart
  5. Current patient of PPG-Cardiology
  6. History of HFrEF

Exclusion Criteria:

  1. Do not have a Biotronik CRT
  2. Have a Biotronik CRT-CIED for less than 60 days
  3. Not being remotely monitored with a Biotronik CRT-CIED
  4. No history of HFrEF
  5. Inability to provide informed consent
  6. Age < 18 years
  7. Lack of internet access or otherwise unable to access MyChart
  8. Pacemaker dependency
  9. Does not meet inclusion criteria

Sites / Locations

  • Parkview Health

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Heart Failure Patients with CRT-CIED

Arm Description

PHR Messaging to notify patient of device transmitted information (i.e. percentage LV pacing)

Outcomes

Primary Outcome Measures

Timeliness of calls to clinic for adjustment in therapy
Patient engagement evaluated through patient survey
Improved percentage of LV pacing

Secondary Outcome Measures

Full Information

First Posted
January 27, 2016
Last Updated
October 28, 2019
Sponsor
Parkview Health
Collaborators
Biotronik, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02682251
Brief Title
Engaging Patients in Heart Failure Management
Official Title
Engaging Patients in Heart Failure Management
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
February 2016 (Actual)
Primary Completion Date
August 2019 (Actual)
Study Completion Date
October 5, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Parkview Health
Collaborators
Biotronik, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
An interventional study to empower congestive heart failure patients who have a cardiac resynchronization therapy-cardiac implantable electronic device (CRT-CIED) by using a personal health record (PHR) to directly message them their device data and send alerts based on percent left ventricular pacing.
Detailed Description
An interventional study to empower congestive heart failure patients who have a cardiac resynchronization therapy-cardiac implantable electronic device (CRT-CIED) by using a personal health record (PHR) to directly message them their device data and send alerts based on percent left ventricular pacing. There will be three phases in this study. In the first phase the investigators will employ a user-centered design approach to better understand what types of information that patients who have a remotely monitored CRT-CIED would find beneficial towards understanding and managing their disease. The investigators also hope to uncover expectations for alert mechanisms and two-way messaging between provider and patient around CIED remote monitoring data. In the second phase the investigators will implement the PHR intervention as designed in phase 1. In the third phase of this study, the investigators will test the PHR intervention in a single arm, 6-month trial. A maximum of 120 participants (including patients and their caregiver, partner, and/or support persons) will be enrolled in the focus groups for phase 1. A maximum of 10 patients will be enrolled in the design session to follow in phase 1. After building the intervention in phase 2, a maximum of 30 patients will be enrolled in the technology trial for phase 3. Enrollment is projected to be complete within six months for phase 1, and within one year for phase 3. In phase 3, adult subjects (N=30) with a diagnosis of congestive heart failure undergoing chronic resynchronization therapy through their CIED will receive interventional messaging through their PHR regarding percent left ventricular pacing. The study duration will commence at the time of informed consent documentation during the first focus group and conclude at the time of the last patient visit during the technology trial. Impact of PHR messaging will be evaluated by timeliness of patient calls to clinic for adjustment in therapy, an improved percentage of LV pacing over 6 months compared to historical controls from the same clinic, as well as self-reported patient engagement. Timeliness of patient calls to clinic will be evaluated through record of patient calls to clinic 6 months prior to study and 6 months during study. Patient engagement will be evaluated through patient survey at start and end of study. Patients will follow standard of care + intervention during study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congestive Heart Failure
Keywords
Cardiac Resynchronization Therapy Devices, Cardiac Resynchronization Therapy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Heart Failure Patients with CRT-CIED
Arm Type
Experimental
Arm Description
PHR Messaging to notify patient of device transmitted information (i.e. percentage LV pacing)
Intervention Type
Other
Intervention Name(s)
PHR Messaging
Intervention Description
PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
Primary Outcome Measure Information:
Title
Timeliness of calls to clinic for adjustment in therapy
Time Frame
6 months during study
Title
Patient engagement evaluated through patient survey
Time Frame
6 months during study
Title
Improved percentage of LV pacing
Time Frame
6 months during study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
FOCUS GROUPS Inclusion Criteria: Remotely monitored with CRT-CIED focus groups 1 & 2: implant ≤ 12 months focus groups 3 & 4: implant ≥ 12 months Current patient of PPG-Cardiology History of HFrEF (heart failure in the setting of reduced ejection fraction) Access to computer and internet *Ability to provide informed consent *Age ≥ 18 years 5 and 6 must apply to caregivers, partners, and/or support persons Exclusion Criteria: Not remotely monitored with CRT-CIED Not current patient of PPG-Cardiology No history of HFrEF Pacemaker dependent Does not have access to computer and internet *Inability to provide informed consent *Age < 18 years *Does not meet inclusion criteria Only 6, 7, and 8 apply to caregivers, partners, and/or support persons TECHNOLOGY TRIAL Inclusion Criteria: Remotely monitored with Biotronik CRT-CIED for more than 60 days Ability to provide informed consent Age ≥ 18 years Willing to have MyChart or proxy to MyChart Current patient of PPG-Cardiology History of HFrEF Exclusion Criteria: Do not have a Biotronik CRT Have a Biotronik CRT-CIED for less than 60 days Not being remotely monitored with a Biotronik CRT-CIED No history of HFrEF Inability to provide informed consent Age < 18 years Lack of internet access or otherwise unable to access MyChart Pacemaker dependency Does not meet inclusion criteria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tammy Toscos, PhD
Organizational Affiliation
Parkview Health
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael Mirro, MD
Organizational Affiliation
Parkview Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Parkview Health
City
Fort Wayne
State/Province
Indiana
ZIP/Postal Code
46845
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is no plan to make individual participant data available.

Learn more about this trial

Engaging Patients in Heart Failure Management

We'll reach out to this number within 24 hrs